Heath Robinson (codebreaking machine)

AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023

Retrieved on: 
星期一, 十月 16, 2023
Keypad, Abstract, Breast cancer, FOLFIRI, Oncology, ESMO, SD, Carcinoma, Colorectal cancer, European Society for Medical Oncology, AMGN, Cancer, KRAS, Myalgia, Cytokine release syndrome, RAS, Hitachi HD44780 LCD controller, MA, Prostate cancer, PR, Love at First Bite, NSCLC, PAN, SCLC, Fever, CRC, Denosumab, Fatigue, CRS, Renal cell carcinoma, ESME, Heath Robinson (codebreaking machine), Congress, Biomarker, AMG, Research and development, Panitumumab, Pembrolizumab, AM, Metastasis, STEAP1, Prostate, Pharmaceutical industry, Medical imaging, Book, Entertainment, Communications satellite, Research, Amgen, Patient

THOUSAND OAKS, Calif., Oct. 16, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across its broad oncology portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress 2023, taking place from October 20-24 in Madrid. Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.

Key Points: 
  • Results from Amgen-sponsored and collaborative studies, including two late-breaking oral presentations, will feature data in a range of tough-to-treat cancers.
  • "Our data at ESMO demonstrate the rapid progress we are making in advancing a portfolio with first-in-class therapies, including metastatic KRAS G12C mutated colorectal cancer and small cell lung cancer," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "These findings illustrate how we are attacking cancer from many different angles to deliver new approaches poised to alter the natural history of disease across many cancers."
  • Amgen will present data from two late-breaking abstracts at ESMO:
    Results from CodeBreaK 300 (Abstract #LBA10), a global, registration-enabling Phase 3 trial evaluating LUMAKRAS (sotorasib) combined with Vectibix (panitumumab) in chemorefractory KRAS G12C-mutated metastatic CRC.

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS CHEMOTHERAPY DATA IN FIRST-LINE KRAS G12C NSCLC AT WCLC

Retrieved on: 
星期日, 九月 10, 2023
WCLC, AMGN, KRAS, Duke University, Amgen, Duke Cancer Institute, DCR, Platinum, Trae tha Truth, Lung cancer, International Association, Medicine, NSCLC, Carboplatin, PFS, Drug resistance, Progression-free survival, Patient, Anemia, Heath Robinson (codebreaking machine), Pemetrexed, Safety, PD-L1, Conference, ORR, Pharmaceutical industry, Fine chemical, Research

THOUSAND OAKS, Calif., Sept. 10, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced exciting data from a study arm of the CodeBreaK 101 clinical trial, a Phase 1b study evaluating LUMAKRAS® (sotorasib) with carboplatin and pemetrexed in adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). These results were featured in an oral presentation at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) in Singapore on Sunday, September 10.

Key Points: 
  • In assessable patients in the second-line setting (n=13), the ORR was 54%, with a DCR of 85% (95% CI: 54.6, 98.1).
  • "Notably, these results follow and further expand upon the Phase 2 investigator-led data demonstrating favorable efficacy and safety of LUMAKRAS plus carboplatin and pemetrexed in the first-line treatment of patients with KRAS G12C-mutated NSCLC."
  • The LUMAKRAS plus chemotherapy combination reported treatment-related adverse events (TRAEs) consistent with LUMAKRAS and other platinum doublet-based approaches.
  • "The CodeBreaK 101 results show exciting efficacy with sotorasib plus chemotherapy and, importantly for a combination treatment, a safety profile consistent with the individual therapies.

AMGEN PRESENTS NEW SCIENTIFIC AND CLINICAL RESEARCH ACROSS ITS DIVERSE ONCOLOGY PORTFOLIO AND PIPELINE AT ASCO 2023

Retrieved on: 
星期四, 六月 1, 2023
AMGN, KRAS, Amgen, KID, Osteoporosis, Research and development, Plasma, RAS, Patient, Panitumumab, Blinatumomab, Myelodysplastic syndrome, Carcinoma, CT, Bi-specific T-cell engager, Multiple myeloma, Panama, Lenalidomide, Lung cancer, MRD, Heath Robinson (codebreaking machine), Inotuzumab ozogamicin, Docetaxel, Abstract, Metastasis, RCT, Cancer, Carfilzomib, NSCLC, Denosumab, Sarcoma, Colorectal cancer, Biomarker, Busulfan, Neoplasm, Pembrolizumab, CRC, Dexamethasone, SCLC, ASCO, Talimogene laherparepvec, American Society of Clinical Oncology, ASCT, Melanoma, Annual general meeting, CDT, Melphalan, Society, Pharmaceutical industry, Medical imaging, Communications satellite, Flour, Glass wool, Vaccine, Nursing, Book, Takeda, Allotransplantation, Research

THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago. More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).

Key Points: 
  • Additional Analyses from DeLLphi-300 Highlight Safety and Clinical Efficacy of Tarlatamab, an Investigational First-in-Class BiTE® Immunotherapy, in Patients with SCLC With Treated and Stable Brain Metastases
    THOUSAND OAKS, Calif., June 1, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new scientific and clinical research across its diverse oncology portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 2-6 in Chicago.
  • More than 25 abstracts from Amgen-sponsored and collaborative studies, including three oral presentations and two poster discussions, will feature data in hard-to-treat tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and small cell lung cancer (SCLC).
  • "Our presentations at ASCO will illustrate how we're advancing novel approaches to address the toughest thoracic and colorectal cancers with limited treatment options," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "We're focused on expanding the reach and impact of our transformative, first-in-class medicines to help more people living with cancer."

Revolution Medicines Reports Fourth Quarter and Year-End 2021 Financial Results and Update on Corporate Progress

Retrieved on: 
星期一, 二月 28, 2022
Phosphorylation, Data, Security (finance), ID, COVID-19, Sanofi, Therapy, Pancreatic cancer, KRAS, Lung cancer, Nasdaq, Merck, Private Securities Litigation Reform Act, Research, G12, Medication, Partnership, Collection, Revolution, U.S. Securities and Exchange Commission, Attention deficit hyperactivity disorder predominantly inattentive, Terminology, Colorectal cancer, Cancer, Disclosure, Pembrolizumab, NSCLC, D, OFF, PD-1, Ras GTPase, Gastrointestinal cancer, AACR, Merck Sharp & Dohme Federal Credit Union, Forward-looking statement, Patient, Merck & Co., GLOBE, Heath Robinson (codebreaking machine), Investigational New Drug, Annual report, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, SHP2, CRC, Conference, Large-cell lung carcinoma, GAAP, MTORC1, Pharmaceutical industry, Video game, Cryptocurrency, G13, IND, Amgen

REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

Key Points: 
  • Revolution Medicines continues to advance our integrated RAS-focused pipeline consisting of innovative RAS(ON) Inhibitors and RAS Companion Inhibitors.
  • R&D Expenses: Research and development expenses were $53.7 million for the quarter ended December 31, 2021, compared to $37.0 million for the quarter ended December 31, 2020.
  • Revolution Medicines will host a conference call and webcast this afternoon,February 28, 2022, at4:30 PM Eastern(1:30 PM Pacific).
  • Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

City of Hope Researchers Help Find Improved Treatment Options for Patients With Advanced Colorectal Cancer

Retrieved on: 
星期二, 十二月 14, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Diabetes, Translational Genomics Research Institute, Instagram, Standard of care, City of Hope, National Comprehensive Cancer Network, Population, Heath Robinson (codebreaking machine), Amgen, U.S. News & World Report, Progression-free survival, Colorectal cancer, EGFR, Korea Disease Control and Prevention Agency, Panitumumab, National Cancer Institute, Cancer, Haematopoietic system, Survival, Biomedical Research, Immunotherapy, News, Gastrointestinal cancer, Center, NCI, Large intestine, Patient, Nausea, KRAS, Trifluridine, Oncology, Twitter, YouTube, CAR, Diabetes, Clinical research, Judy, Technology, Diarrhea, Pharmaceutical industry, Hope, Research, The Lancet, City, Facebook

City of Hope, a world-renowned cancer research and treatment organization, today announced study results of a Phase 2 clinical trial showing monotherapy with sotorasib resulted in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal cancer.

Key Points: 
  • City of Hope, a world-renowned cancer research and treatment organization, today announced study results of a Phase 2 clinical trial showing monotherapy with sotorasib resulted in anti-tumor activity and a favorable benefit-risk profile among heavily pretreated patients with advanced colorectal cancer.
  • Colorectal cancer is the third most common cancer diagnosed in the United States and the second leading cause of cancer death, according to the Centers for Disease Control and Prevention.
  • Currently, overall response rate for patients with recurrent metastatic colorectal cancer who take approved options, such as trifluridine and regorafenib, ranges from 1-4%, Fakih said.
  • A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals in cancer by U.S. News & World Report.

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

Retrieved on: 
星期三, 十一月 10, 2021
MTORC1, Merck & Co., Lung cancer, Therapy, Security (finance), Terminology, D, SOS1, COVID-19, PD-1, Cancer, Collection, Phosphorylation, SHP2, Safety, Gastrointestinal cancer, Research, Forward-looking statement, Conference, U.S. Securities and Exchange Commission, GLOBE, Merck Sharp & Dohme Federal Credit Union, GAAP, Patient, Sanofi, Data, Private Securities Litigation Reform Act, Lists of World Heritage Sites, Heath Robinson (codebreaking machine), Pembrolizumab, ID, CRC, OFF, Pancreatic cancer, Tetrahedral carbonyl addition compound, Colorectal cancer, Merck, Revolution, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Ras GTPase, AACR, Partnership, Neoplasm, Company, KRAS, Investigational New Drug, Nasdaq, Pharmaceutical industry, Sewage, Aquaculture

REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted drugs to inhibit frontier targets that drive and sustain RAS-addicted cancers, today announced its financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.

Key Points: 
  • Revolution Medicines is sponsoring the RMC-4630-03 study under its global partnership with Sanofi and conducting the trial in collaboration with Amgen.
  • Revolution Medicines will host a conference call and webcast this afternoon,November 10, 2021, at4:30 PM Eastern(1:30 PM Pacific).
  • Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.
  • Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.